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SUMMARY
Objectives. The purpose of this study was to correlate acute invasive fungal rhinosinusitis 
(AIFRS) and chronic invasive fungal rhinosinusitis with underlying diseases, aetiological 
microorganisms, clinical symptoms, radiological findings, and surgical and medical treat-
ment to determine the subset of patients who require more accurate diagnostic investigation 
and to prevent irreversible complications. 
Methods. This retrospective monocentric study included 17 patients who underwent endo-
scopic sinus surgery evaluated by paranasal computed tomography and magnetic resonance 
imaging. Age, sex and symptoms, and location of the invasive fungal infection and the 
causative fungus were analysed. 
Results. In total, 4 patients were affected by the AIFRS form, and 13 by the chronic form. 
Diabetes mellitus was reported in 41.17% of cases, and haematological diseases in 23.52%. 
The maxillary sinuses were involved in 47.05% of cases and sphenoidal sinuses in 52.94%; 
Aspergillus fumigatus was the fungus in 76.47% of cases, and Zygomycetes in 23.53%.
Conclusions. An understanding of the different types of fungal sinusitis and knowledge of 
their features play a crucial role in reaching prompt diagnosis and initiation of appropriate 
therapy, which is essential to avoid a protracted or fatal outcome.
KEY WORDS: Aspergillus, Mucormycosis, invasive fungal rhinosinusitis, isavuconazole, 
liposomal amphotericin B
RIASSUNTO
Obiettivi. Nonostante i progressi in termini di trattamento, la mortalità nei casi di rinosinu-
site fungina invasiva rimane elevata, pertanto, scopo dello studio è stato correlare le forme 
acute invasive e quelle croniche con patologie concomitanti, agenti eziologici, i sintomi 
clinici, radiologia e trattamento, al fine di identificare e trattare i pazienti con prognosi 
peggiore. 
Metodi. Il seguente studio retrospettivo monocentrico ha incluso 17 pazienti sottoposti a 
chirurgia endoscopica sinusale, valutati mediante TC e RM e analizzati per età, sesso, sin-
tomi, sede dell’infezione fungina invasiva e microrganismi eziologici. 
Risultati. 4 pazienti sono risultati affetti dalla forma invasiva acuta,13 pazienti dalla forma 
cronica. Il diabete mellito è stato riscontrato nel 41,17% dei casi, malattie ematologiche 
nel 23,52%. I seni mascellari sono risultati coinvolti nel 47,05% dei pazienti e seni sfenoi-
dali nel 52,94%; Aspergillus ha provocato il 76,47% dei casi, Zigomiceti il 23,53%. 
Conclusioni. Un’adeguata comprensione dei diversi tipi di sinusite fungina e la conoscen-
za delle loro caratteristiche svolgono un ruolo cruciale ai fini di una diagnosi precoce e 
l’avvio di una terapia appropriata con lo scopo di ridurne la mortalità.
PAROLE CHIAVE: Aspergillus, Mucormycosis, rinosinusite fungina invasiva, 
Isavuconazolo, amfotericina B liposomiale
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Introduction
The concept of invasiveness for a fungal infection refers to 
the potential for fungal hyphae to invade epithelial tissue 
with potential neural and vascular involvement 1,2. We can 
categorise invasive fungal rhinosinusitis (IFRS) into three 
subgroups: acute invasive fungal rhinosinusitis (AIFRS), 
chronic invasive fungal rhinosinusitis and chronic granu-
lomatous invasive fungal rhinosinusitis 3.
Invasive fungal rhinosinusitis (IFRS) generally occurs in 
immunocompromised patients, i.e. those with haemato-
logical malignancies or undergoing chemotherapy or allo-
geneic haematopoietic transplantation, patients with AIDS, 
and in poorly controlled diabetic patients undergoing im-
munosuppressive therapy 4.
Acute invasive fungal rhinosinusitis (AIFRS) is defined by 
a time course of less than 4 weeks’ duration, with predomi-
nant vascular invasion. The infection results from rapid 
spread of fungi from the paranasal sinuses to the adjacent 
orbits and central nervous system with hyphal invasion of 
blood vessels, vasculitis with thrombosis, haemorrhage, 
tissue infarction and acute neutrophilic infiltrates with a 
necrotising pathological reaction 5.
Chronic IFRS is an indolent infection with a slow destruc-
tive process that most commonly affects the ethmoid and 
sphenoid sinuses, but may involve any paranasal sinus 6,7.
Despite improvements in both medical and surgical thera-
pies, the mortality of patients with IFRS remains high (50-
80%) mostly due to invasion of the orbit and intracranial 
cavity 8,9; in fact, early and accurate diagnosis is essential 
because prognosis is often governed by the rapid initiation 
of antifungal therapy and/or surgical debridement 10.
Therefore, the purpose of this article was to correlate AI-
FRS and chronic indolent IFRS with underlying diseases, 
aetiological microorganisms, clinical symptoms, radiologi-
cal findings, and surgical and medical treatment.
The study aimed to aid clinicians in the decision-making 
process by systematically assembling previously published 
evidence and new updates on medical treatment, and to 
consider the possibility of identifying a subset of patients 
who require more accurate diagnostic investigation to pre-
vent irreversible complications.
Materials and methods
This single-centre retrospective study included 17 patients 
affected by IFRS who underwent endoscopic sinus surgery 
(ESS) at the ENT Department in San Luigi Gonzaga Hos-
pital, Turin, Italy between January 2016 and January 2020. 
For inclusion, patients were required to have histopatholog-
ically confirmed IFRS, defined by the evidence of fungal 
hyphae in the mucosa of the affected sinus. Patients aged 
< 18 years, those who had previously received nasal sur-
gery or who had been diagnosed with non-invasive fungal 
rhinosinusitis were excluded.
Patients’ records were analysed retrospectively for pre-
senting symptoms, underlying diseases, causative micro-
organisms, radiological findings, and medical and surgical 
treatment. All enrolled patients were evaluated preop-
eratively with paranasal computed tomography (CT) and 
magnetic resonance imaging (MRI). In addition, age, sex 
and symptoms as well as the location of the invasive fun-
gal infection and the causative fungus were analysed for 
each patient.
Tissue samples were collected for both microbiological 
and histopathological examination to provide a definitive 
diagnosis. A mucosal biopsy sample was also collected 
from the sinus wall and evaluated histologically. A swab 
sample was taken from purulent sinus secretions and sent 
to the microbiology laboratory for bacterial culture under 
both aerobic and anaerobic conditions. When feasible, 
galactomannan and beta-D-glucan were tested in blood 
samples. Galactomannan (GM) is a molecule that is pre-
sent in the cellular walls of Aspergillus species and can 
be secreted extracellularly. Several studies have shown 
that the determination of GM is beneficial for diagnosis 
and, together with 1,3-beta-D-glucan (BDG) antigens, 
can improve the sensitivity of invasive aspergillosis di-
agnosis 11.
All patients underwent debridement through endoscopic 
sinus surgery (ESS) under general anaesthesia as the first 
choice to remove the entire lesion in the sinus using rigid 
endoscopes (Karl Storz Endoskope, Germany) with a di-
ameter of 4 mm and viewing angles of 0°, 45° and 70°. Af-
ter surgery, specific medical antifungal treatment was initi-
ated as prescribed by an infectious disease specialist, and 
in the case of positive cultures indicating bacterial coinfec-
tion, the type of antibiotic therapy was determined by an-
tibiogram results. All patients were prospectively followed 
through endoscopic monitoring performed at intervals of 
15, 30, 60, 90 days, 6 months and 1 year after surgery. Us-
ing a rigid endoscope, secretions and crusts were removed 
at the outpatient department and postoperative home treat-
ment included nasal saline irrigation twice a day for at least 
3 months. Therapeutic success was clinically and endo-
scopically defined as patients who were asymptomatic at 6 
months after completing the antifungal therapy. Follow-up 
with MRI was only performed when recurrence was sus-
pected. No patient was lost during the follow-up period. 
This study was in line with the guidelines of the Helsinki 
Declaration for ethical consideration. Accordingly, written 
informed consent was obtained from all patients. Categori-
cal data are presented as frequencies.
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Results
The study included 17 patients (8 women and 9 men) affect-
ed by IFRS, diagnosed between January 2016 and January 
2020. Their median age was 57 years, range: 31-82 years, 
and the interquartile range (IQR) was 27 ± 14.77 years. In 
total, 4 patients were affected by the AIFRS form (Tab. I) 
and 13 patients had the chronic indolent form (Tab. II).
The most common underlying disease was diabetes mellitus 
reported in 7 cases (41.17%) followed by haematological 
diseases in 4 cases (23.52%): myelodysplastic syndrome 
(n = 1), non-Hodgkin lymphoma (n = 1) and acute myeloid 
leukaemia (n = 2). Furthermore, 5 patients (29.41%) had 
neutropenia. An autoimmune condition, rheumatoid arthri-
tis, was recognised in 1 case. Another cause of immunode-
ficiency was steroid therapy, found in 1 patient. Alveolar 
rhabdomyosarcoma together with chemoradiotherapy and 
neutropenia were observed in 1 patient. As reported in Ta-
bles I and II, several patients showed different associations 
of these underlying diseases, with different symptoms oc-
curring simultaneously in the same patient.
Facial pain and headache were the most commonly re-
ported presenting signs and symptoms in 12 (70.58%) 
and 8 (47.05%) patients, respectively; 6 patients had ocu-
lar diseases (35.29%): diplopia was observed in 4 patients 
(23.52%), proptosis in 3 (17.64%) and bilateral amaurosis 
in 1 case (5.88%). Cranial nerve palsy (VI) was present in 
2 patients (11.76%) and trigeminal neuralgia in 1 patient 
(5.88%). The average time between the onset of symptoms 
to presentation in the emergency room and the beginning of 
the diagnostic process was about 2 days for AIFRS and 10 
days for the chronic indolent form. No patient had received 
medical treatment at other healthcare facilities.
CT and MRI were used preoperatively to determine the 
extent of fungal invasion: 14 (82.35%) patients had uni-
lateral involvement of the paranasal sinuses and one of 
them (5.88%) also showed the simultaneous involvement 
of two different sinuses, the maxillary and sphenoid sinus 
(#4 Tab. II) on the right side. Three patients (17.64%) had 
bilateral fungal invasion.
Our data also showed involvement of the maxillary sinus-
es in 8 patients (47.05%) and of the sphenoid sinuses in 9 
patients (52.94%); there was simultaneous involvement of 
both paranasal sinuses in 1 patient (5.88%). The principal 
radiologic findings with CT and MRI are summarised in 
Tables III and IV, respectively.
Five patients showed extra-sinus involvement of the fun-
gal disease (29.41%): the cavernous sinus was the site of 
the most frequent dissemination being present in 5 patients 
(29.41%), followed by 2 cases (11.76%) with intracranial 
involvement and 2 cases (11.76%) with thrombosis of the 
internal carotid artery (ICA) (11.76%). Ocular manifesta-
tions were also detected: orbital and optic nerve involve-
ment (n = 2, 11.76%) and VI cranial nerve palsy (n = 4, 
23.52%).
All patients underwent endoscopic debridement with endo-
scopic sinus surgery (ESS) under general anaesthesia, with 
complete removal of all necrotic tissue. No other surgical 
procedures were performed. The time from the patient’s ar-
rival at the hospital to ESS varied from less than 1 day to 
70 days (median: 35 days, IQR: 57.5 days): all AIFRS pa-
tients underwent emergency ESS immediately. In the group 
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with the chronic indolent form, the delay to surgery in 1 pa-
tient (#13) was linked to the onset of concomitant diseases 
which required further investigations by other specialists 
and, consequently, postponed the anaesthesiologic eligibil-
ity for surgery.
Bilateral nasal packing was performed in each patient and 
was removed 48 hours after surgery. No intraoperative 
complications occurred (Figs. 1-3).
Histological examination confirmed the invasive fungal 
disease in all cases: Aspergillus was detected in 13 patients 
(76.47%) (1 patient in the AIFRS group and 12 patients in 
the group with the chronic form), and Zygomycetes was 
detected in 4 patients (23.52%): the intraoperative view 
showed typical friable cheesy-like yellow to brown mate-
rial in sinus cavities, confirming the fungal aetiology of the 
disease already diagnosed macroscopically.
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Table III. Radiologic characteristics of IFRS in non-contrast CT scan.
Sinus involved Calcification Bony sclerosis Bone erosion
MS 10 (58.8) 3 (17.6) 3 (17.6)









IFRS: invasive fungal rhinosinusitis; MS: maxillary sinus; SS: sphenoid sinus.
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Microbiological analysis was also performed: Aspergillus 
fumigatus was isolated in 7 patients (41.17%), Rhizomucor 
in 1 (5.88%), and Penicillium in 1 case (5.88%). The causa-
tive microorganism could not be determined in 8 patients 
(47.05%).
Bacterial co-infections occurred in 6 patients (35.29%) and 
were most frequently caused by Staphylococcus species 
and Pseudomonas aeruginosa (11.76%), followed by one 
case of Streptococcus pyogenes (5.88%), one case of Actin-
omyces (5.88%) and one of Haemofilus influenzae (5.88%).
All patients promptly started systemic antimycotic treat-
ment. Voriconazole was administered to 13 patients 
(76.47%); the 200 mg bid intravenous formulation was 
preferred initially and was switched to an oral formu-
lation when possible, on average after a period of 3.41 
months (range = 20 days-12 months, median = 2 months, 
IQR  =  2); 4 patients (23.52%) were treated with liposo-
mal amphotericin B (L-AmB) (range = 3 days-12 months, 
median = 0.74 months, IQR = 1.88) with dosages from 3 
to 10 mg/kg/day; in 3 selected cases, isavuconazole with a 
dosage of 200 mg/day in intravenous or oral formulation or 
posaconazole at 300 mg/day were also used in association.
In total, 15 patients are still in follow-up with a mean 
Table IV. Radiologic findings of IFRS in MRI.
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IFRS: invasive fungal rhinosinusitis; MS: maxillary sinus; SS: sphenoid sinus; ICA: internal carotid artery.
Figure 1. Patient #2 in the AIFRS group – (A, B) Coronal CT scan shows 
an opacity of the right maxillary sinus (MS) with associated multiple foci of 
microcalcifications (white arrowhead) and sclerosis of the MS walls by reac-
tive osteitis. Focal interruption (white arrow) of the lateral wall is also present. 
(C) Coronal T2-MRI shows marked hypointense signal with areas of hyperin-
tense signal in the lateral and inferior recess of the MS. (D) Intraoperative view 
showing typical friable cheesy-like yellow to brown material on the floor of the 
maxillary sinus.
Figura 2. Patient #4 in the AIFRS group – Axial (A) and coronal (B) CT scans 
display heterogeneous opacity of the sphenoid sinuses (SS) with associated 
microcalcification (white arrowhead), thickening and sclerosis of the bone sur-
rounding the SS, and multiple interruptions of its bony wall (black arrow). (C) 
Axial gadolinium-enhanced T1-weighted MRI demonstrates a marked hypoin-
tense signal (asterisk) in the left SS with inflamed mucosa at the periphery. 
(D) Endoscopic removal of fungal concretion after opening the anterior wall 
of the left SS. 
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duration of 20.12 months (range  =  0.06-58 months; me-
dian = 16 months, IQR = 24), 2 patients died (11.76%), 1 
patient from cerebral ischaemia and the other from uncon-
trolled rhinocerebral infection.
Only one relapse was observed with persistence of fungal 
pathology in the sphenoidal sinus, requiring revision sur-
gery at 6 months and with a histological diagnosis of As-
pergillus.
Discussion
A diagnosis of IFRS requires histopathologic evidence of 
fungi invading nasal tissue, characterised by a dense ac-
cumulation of hyphae, the occasional presence of vascular 
invasion and a diffuse inflammatory reaction 12.
Acute IFRS is characterised by a rapid evolution and is as-
sociated with a high mortality rate that can reach 100% in 
cases of intracranial mycotic dissemination: Zygomycetes 
(Rhizopus, Mucor, Rhizomucor) and species of Aspergillus 
are the most common aetiologic agents in the sinonasal cav-
ity, with more frequent neurovascular and orbital invasion 13.
CT scans show homogeneous opacification of the sinus 
with calcification, adjacent bone erosion, dehiscence of 
the lateral sphenoid’s recess with signs of remodeling in 
the wall of the sphenoid sinus, especially in immunocom-
promised patients 14. Signal intensity was evaluated using 
MRI, and was grouped into three categories: slightly T1-
weighted iso- or hypointense, markedly T2-weighted hy-
pointense (near signal void), and peripheral enhancement 
of the surrounding mucosa. On MRI, orbital and intracrani-
al involvement were present as suggested findings, together 
with perineural spread and expansion outside the confines 
of the sinonasal cavity with cavernous sinus involvement 
or thrombosis of the ICA, and have been reported previ-
ously 15.
Clinical suspicion of AIFRS should be raised in the immu-
nocompromised patient presenting with new-onset, rapidly 
progressive sinusitis or facial discomfort 16.
In our experience, symptomatology in AIFRS patients was 
very evident when a sphenoidal localisation was present 
(proptosis, diplopia, cranial nerve palsy (VI), trigeminal 
neuralgia, or visual abnormalities) because of a connec-
tion between the sphenoidal sinus and anatomic structures 
such as the ICA, cavernous sinus, optic nerve, eyehole, or 
brain 17. Therefore, thanks to the rapidity of onset, patients 
with AIFRS came immediately to our clinic, and we per-
formed an emergency surgical intervention thereby pre-
venting serious cerebral and ocular complications. On the 
other hand, patients with the chronic indolent form showed 
nonspecific and slowly progressive signs and symptoms 
that did not arouse suspicion in the patient, delaying access 
to the emergency room and consequently, to the diagnostic 
and therapeutic process.
As reported in a review of over 800 patients by Turner et 
al., Aspergillus spp. and Mucor spp. can both be found in 
neutropenic patients and in those with chronic systemic 
steroid treatment, whereas Mucor spp. has a propensity for 
diabetic and iron-overloaded patients 18.
Neutropenia plays a key role as a factor contributing to the 
development of infection in patients with haematological 
disease. In the present study, 29.41% of patients were af-
fected by a severe neutropenic state, defined as a neutro-
phil count <  500/mmc  19, and 23.52% of patients had an 
underlying haematological disease, such as non-Hodgkin 
lymphoma, myelodysplastic syndrome or acute myeloid 
leukemia. Other underlying conditions included poorly 
controlled DM, immunosuppressive treatment and corti-
costeroid exposure 20.
Figura 3. Patient #1 in the AIFRS group – (A) Coronal CT scan showing com-
plete opacification of the right sphenoid sinus with optical right nerve canal wall 
erosion (black arrows). (B) Axial MRI with contrast shows a hypointense signal in 
a large space-occupying lesion in the right SS extending into the right cavernous 
sinus (asterisk). The cavernous carotid artery appears unobstructed. (C) Endocra-
nial mycotic abscess (white arrow) with inflamed mucosa within Meckel’s cave 
on the right at periphery at day 41. (D) Intraoperative view during endoscopic si-
nus surgery in the right SS. (E) Absence of motility of the right eye in lateral gaze 
related to the deficit of the right lateral rectus muscle for abducens nerve palsy.
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Our data show a significant proportion of patients infect-
ed by Aspergillus fumigatus in the chronic indolent group 
(92.30%) and only one patient was affected (pt#1) by Zy-
gomycetes (7.70%). Conversely, in AIFRS patients, Zygo-
mycetes were the fungi mainly responsible for the infec-
tion and only in one patient (#2) was Aspergillus fumigatus 
isolated.
In line with the results obtained in our previous study 21, it 
is still unclear why the microbiological evidence for fungal 
disease was negative in 8 cases, although the radiologic and 
endoscopic intraoperative findings were strongly indicative 
of IFRS.
Treatment for both groups was based on a combination of 
antifungal therapy, reversal of immunocompromising fac-
tors, surgical debridement through ESS when possible and 
obtaining material for histopathological and cultural ex-
aminations 22.
Vaughan et al. analysed 37 mucormycosis cases and found 
no significant difference in survival between patients hav-
ing surgery 1-30 days after diagnosis 23. These data agree 
with our study, with an onset of treatment on average 32.41 
days after diagnosis, highlighting why the start of treatment 
should be initiated as soon as IFRS is diagnosed.
For an early surgical approach, the correct medical therapy 
must be promptly selected based on the fungal pathogen 
affecting the patient: we can generalise that the current 
mainstay of therapy for IFRS is L-AmB (recommended 
dosage from 3 to 10 mg/kg per day) 24. For invasive asper-
gillosis, treatment with voriconazole is recommended pri-
marily for patients with cranial nerve involvement. Alter-
natively, isavuconazole, a second generation triazole, has 
been shown to be as effective as voriconazole and better 
tolerated. For mucormycosis IFRS treatment, L-AmB and 
posaconazole are the most recommended drugs, together 
with isavuconazole which can be administered in patients 
in whom amphotericin B cannot be administered because 
of intolerance or in the case of kidney disease. Combi-
nation therapy with two drugs has been reported. In the 
current study, 76.47% of our patients were treated with 
voriconazole, showing fewer systemic side effects than L-
AmB, a favourable bone penetration and good tolerance 
as maintenance therapy.
Isavuconazole is an innovative and effective therapeutic 
option with a very high oral bioavailability (98%), a good 
profile of tolerability and efficacy and a low risk of inter-
actions with other drugs  25. However, further studies are 
needed to better integrate isavuconazole in the manage-
ment of patients with IFRS, with the aim to define a clear 
correlation between plasma levels and efficacy end points 
and to identify the best therapeutic window in which to ad-
minister it.
Due to the relative rarity of AIFRS, our data was limited to 
acute and chronic indolent IFRS, and unfortunately did not 
include granulomatous forms, thus precluding larger cohort 
studies. The results are dependent on the quality of the lim-
ited data available, but are in line with the current literature. 
Moreover, our study focused on differentiating acute and 
chronic indolent forms, which was not always easy to rec-
ognise with certainty in previous studies, so as to guide the 
most appropriate diagnostic and therapeutic process.
Conclusions
Invasive fungal rhinosinusitis is a difficult infection to diag-
nose and treat. Early diagnosis is the key to managing IFRS 
successfully, and with a systematic approach, it is possible 
to improve survival, taking into account the context of the 
temporal course of the diagnostic work-up and treatment. 
The goal is diagnosis of the disease at an earlier stage while 
it is confined to the sinonasal cavities before mucosal dis-
semination. A multidisciplinary approach consisting of 
antifungal therapy, surgical debridement, and reversal of 
predisposing conditions is the best therapy to improve sur-
vival.
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